Please assess the completion status of the following clinical trial:

Trial Title: Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or Type 2 diabetes mellitus~* 18 years or older~* Meet specific requirements for diabetic retinopathy~* Free of severe or chronically disabling conditions, except diabetes, diabetic retinopathy and diabetic macular edema~* Hemoglobin A1c (HbA1C) ≤13.0%~Exclusion Criteria:~* History of panretinal photocoagulation for diabetic retinopathy, conditions that might affect the progression of diabetic retinopathy, or unstable angina~* Investigators, site personnel directly affiliated with the study and their families~* Presence of eye disorders that may affect the progression of diabetic retinopathy or cause vision loss~* Presence of medical disorder, cancer, or elevated laboratory measurements that could represent a safety risk during the study~* Women who are pregnant, breastfeeding, intend to become pregnant, or who are sexually active without using an acceptable method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruboxistaurin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).